Future cardiology最新文献_第2页

Cost-effectiveness of continuous real-time intracardiac recurrent event detection and alerting in high-risk acute coronary syndrome patients.

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1080/14796678.2025.2457831

Gillian D Sanders Schmidler, M Sasha John, Jeffrey D Voigt, Mitchell W Krucoff

{"title":"Cost-effectiveness of continuous real-time intracardiac recurrent event detection and alerting in high-risk acute coronary syndrome patients.","authors":"Gillian D Sanders Schmidler, M Sasha John, Jeffrey D Voigt, Mitchell W Krucoff","doi":"10.1080/14796678.2025.2457831","DOIUrl":"10.1080/14796678.2025.2457831","url":null,"abstract":"Background: ALERTS was a pivotal randomized clinical trial (RCT) evaluating an intracardiac monitor with real-time alerting in high-risk acute coronary syndrome patients. The cost-effectiveness however is unknown.Method: A decision model estimated health effects and costs of implanting a Guardian device in a target patient population, compared to current standard-of-care (SOC). Health and economic outcomes were modeled using ALERTS trial results and relevant literature.Results: Base-case analysis indicated an incremental lifetime cost of $21,988 with Guardian as compared to SOC (increase of 0.18 life years or 0.37 quality-adjusted life years (QALY)). The incremental cost-effectiveness ratio (ICER) was $121,056/LY or $58,668/QALY.Conclusion: Real-time intracardiac monitoring with patient alerting was cost-effective using conventional thresholds in acute coronary syndrome (ACS) patients at high-risk for recurrent events.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"83-93"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis.

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2025-01-30 DOI: 10.1080/14796678.2025.2457898

Ioannis Kyriakoulis, Andreas Tzoumas, Konstantinos G Kyriakoulis, Ioannis Kardoutsos, Athina Ntoumaziou, Sanjana Nagraj, Damianos G Kokkinidis, Leonidas Palaiodimos

{"title":"Multivalvular vs single-valve infective endocarditis: a systematic review and meta-analysis.","authors":"Ioannis Kyriakoulis, Andreas Tzoumas, Konstantinos G Kyriakoulis, Ioannis Kardoutsos, Athina Ntoumaziou, Sanjana Nagraj, Damianos G Kokkinidis, Leonidas Palaiodimos","doi":"10.1080/14796678.2025.2457898","DOIUrl":"10.1080/14796678.2025.2457898","url":null,"abstract":"Background: Infective endocarditis is characterized by the colonization of heart valves by virulent microorganisms. It commonly manifests as involvement of a single heart valve -single-valve infective endocarditis (SIE), while in some patients, two or more heart valves are concomitantly infected -multivalvular infective endocarditis (MIE). The risk of complications and prognosis of MIE as opposed to SIE are unknown.Methods: We performed a systematic search in MEDLINE and Scopus for studies of patients with MIE and SIE. The outcomes of interest included mortality, heart failure, systemic embolic events, and need for surgery.Results: Οf 1,124 identified studies, eleven met the inclusion criteria. MIE was reported in 20.4% of the total patients. Compared to SIE, MIE was associated with increased risk of short-term mortality (RR: 1.29, 95% CI: 1.19-1.39), one-year mortality (RR: 1.20, 95% CI: 1.08-1.34), heart failure (RR: 1.31, 95% CI: 1.12-1.54), systemic embolic events (RR: 1.12, 95% CI: 1.02-1.22), and need for subsequent surgical management (RR: 1.22, 95% CI: 1.05-1.41).Conclusions: Patients with MIE have a higher likelihood of poor prognosis compared to patients with SIE. A high clinical suspicion of this condition and timely diagnosis and management are imperative while managing patients with infective endocarditis.Protocol registration: PROSPERO CRD42023486674.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"113-121"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current approach to atherosclerotic cardiovascular disease risk prediction. 目前预测动脉粥样硬化性心血管疾病风险的方法。

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2024-11-24 DOI: 10.1080/14796678.2024.2433349

Wahab J Khan, Dinesh K Kalra

引用次数: 0

Current and future role of PCSK9 inhibitors in ASCVD prevention. PCSK9抑制剂在ASCVD预防中的当前和未来作用

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2025-01-05 DOI: 10.1080/14796678.2025.2450189

Antonio Greco, Davide Capodanno

引用次数: 0

Congenital cardiac surgical simulation: bridging global workforce gaps and optimizing outcomes.

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2025-01-25 DOI: 10.1080/14796678.2025.2458402

Mimi X Deng, Dominique Vervoort, Israel Valverde, Shi-Joon Yoo, Brandon Peel, Rachel D Vanderlaan, David J Barron, Osami Honjo

引用次数: 0

Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.

IF 1.6

Future cardiology Pub Date : 2025-02-01 Epub Date: 2025-02-02 DOI: 10.1080/14796678.2025.2460909

Arif Albulushi, Shabib Al-Asmi, Moosa Al-Abri, Hatem Al-Farhan

{"title":"Elevated Lp(a) and its association with cardiac fibrosis in group II pulmonary hypertension patients.","authors":"Arif Albulushi, Shabib Al-Asmi, Moosa Al-Abri, Hatem Al-Farhan","doi":"10.1080/14796678.2025.2460909","DOIUrl":"10.1080/14796678.2025.2460909","url":null,"abstract":"Background: Group II Pulmonary Hypertension (PH) secondary to Heart Failure with preserved Ejection Fraction (HFpEF) is associated with significant morbidity and mortality. Lipoprotein(a) [Lp(a)] is a novel biomarker implicated in cardiovascular pathology, yet its role in myocardial fibrosis within this population remains underexplored. This study investigates the association between elevated Lp(a) levels and cardiac fibrosis to improve understanding of its prognostic and diagnostic utility.Methods: This retrospective cohort study included 100 patients with Group II PH secondary to HFpEF. Serum Lp(a) levels were quantified using enzymatic assays, and myocardial fibrosis was assessed using Cardiac Magnetic Resonance Imaging (CMR) techniques, including T1 mapping and late gadolinium enhancement (LGE). Statistical models adjusted for confounding factors.Results: Elevated Lp(a) levels were significantly associated with increased myocardial extracellular volume (31% vs. 27%, p < 0.01), prolonged native T1 times, and increased odds of myocardial scar formation. Structural cardiac changes correlated with Lp(a) concentrations.Conclusion: Elevated Lp(a) is a key marker of myocardial fibrosis and structural remodeling in Group II PH secondary to HFpEF. Routine Lp(a) measurement may enhance risk stratification and inform therapeutic strategies.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"95-102"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current landscape of clinical management for systemic light chain amyloidosis.

IF 1.6

Future cardiology Pub Date : 2025-01-31 DOI: 10.1080/14796678.2025.2460392

Andrew Staron, Vaishali Sanchorawala

引用次数: 0

Comparative efficacy of single-coil versus dual-coil ICD leads: a meta-analysis of clinical outcomes.

IF 1.6

Future cardiology Pub Date : 2025-01-30 DOI: 10.1080/14796678.2025.2459542

Muhammad Hamza Shuja, Syed Hasan Shuja, Fabeeha Shaheen, Ramish Hannat, Firzah Shakil, Abeera Farooq Abbasi, Minal Hasan

{"title":"Comparative efficacy of single-coil versus dual-coil ICD leads: a meta-analysis of clinical outcomes.","authors":"Muhammad Hamza Shuja, Syed Hasan Shuja, Fabeeha Shaheen, Ramish Hannat, Firzah Shakil, Abeera Farooq Abbasi, Minal Hasan","doi":"10.1080/14796678.2025.2459542","DOIUrl":"https://doi.org/10.1080/14796678.2025.2459542","url":null,"abstract":"Background: Implantable cardioverter-defibrillators (ICDs) are essential for reducing sudden cardiac death in patients at risk of ventricular arrhythmias. The choice of ICD lead - single-coil or dual-coil - can influence device performance and patient outcomes. This meta-analysis evaluates the comparative efficacy and safety of single-coil versus dual-coil ICD leads to inform clinical decision-making.Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar was performed up to October 2024. Only randomized controlled trials (RCTs) comparing single-coil and dual-coil ICD leads were included. Outcomes assessed included defibrillation threshold (DFT), first-shock efficacy, all-cause mortality, cardiovascular mortality, shock impedance, and peak current.Results: Seven RCTs involving 1,614 patients were analyzed. Single-coil leads demonstrated superior first-shock efficacy (OR: 1.60; p = 0.05), reduced all-cause mortality (RR: 0.63; p = 0.02), and better peak current (MD: -2.29; p = 0.02). DFT and cardiovascular mortality were comparable between groups, while dual-coil leads exhibited lower shock impedance (MD: 18.26; p < 0.00001).Conclusions: Single-coil ICD leads are associated with improved first-shock efficacy and reduced all-cause mortality, suggesting their potential superiority in certain patient populations. Further research is warranted to refine lead selection criteria.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current landscape of congenital heart disease management during pregnancy.

IF 1.6

Future cardiology Pub Date : 2025-01-28 DOI: 10.1080/14796678.2025.2458404

Gurleen Wander, Mark R Johnson

引用次数: 0

A nuanced scrutiny of the segmental renal artery spectral Doppler in "Pickering" the right diagnosis.

IF 1.6

Future cardiology Pub Date : 2025-01-23 DOI: 10.1080/14796678.2025.2457933

Adee Elhamdani, Kirtivardhan Vashistha, Laith Alhuneafat, Tala Altarawneh, Robert Biederman, John Travis Wilson, Wilbert S Aronow, Vinh Nguyen

引用次数: 0